Key result
Triflusal did not significantly differ from aspirin in preventing vascular death, cerebral infarction, myocardial infarction, or major hemorrhage (12.7% vs 13.9%; OR 1.11, 95% CI 0.64-1.94).
Why the study?
Does triflusal reduce the composite of vascular death, cerebral ischemic infarction, nonfatal myocardial infarction, or major hemorrhage in patients with recent ischemic stroke or TIA compared to aspirin?
Population
431 patients who experienced either an ischemic stroke or TIA within 6 months from enrollment, from a Latin…
Comparison
Triflusal 600 mg daily for a mean of 586 days vs Aspirin 325 mg daily for a mean of 586 days
Design
RCT, randomized, double-blind
Follow-up
mean of 586 days
Authors
Loading...
Triflusal matches aspirin on the primary composite in recent stroke/TIA; confirms similar efficacy and supports alternative antiplatelet evaluation.
RCT (n=431)
Double-blind
randomized
Yes
Does triflusal reduce the composite of vascular death, cerebral ischemic infarction, nonfatal myocardial infarction, or major hemorrhage in patients with recent ischemic stroke or TIA compared to aspirin?
Odds Ratio: 1.11 (95% CI 0.64–1.94)
Absolute Event Rate: 12.7% vs 13.9%
In a pilot trial of patients with recent ischemic stroke or TIA, triflusal showed similar efficacy to aspirin for secondary prevention but was associated with a significantly lower risk of hemorrhagic complications.
Culebras et al. (2004) conducted an RCT in ischemic stroke or TIA (n=431). Triflusal vs. Aspirin 325 mg daily was evaluated on incidence of vascular death, cerebral ischemic infarction, nonfatal myocardial infarction, or major hemorrhage (OR 1.11, 95% CI 0.64 to 1.94). Triflusal did not significantly differ from aspirin in preventing vascular death, cerebral infarction, myocardial infarction, or major hemorrhage (12.7% vs 13.9%; OR 1.11, 95% CI 0.64-1.94).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: